Want to see AU:PYC full AI Analyst Report?
Total Valuation
PYC Therapeutics Limited has a market cap or net worth of AU$1.75B. The enterprise value is AU$1.21B.
Market CapAU$1.75B
Enterprise ValueAU$1.21B
Share Statistics
PYC Therapeutics Limited has 984,210,450 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding984,210,450
Owned by Insiders0.06%
Owned by Institutions<0.01%
Financial Efficiency
PYC Therapeutics Limited’s return on equity (ROE) is -0.06 and return on invested capital (ROIC) is -7.47%.
Return on Equity (ROE)-0.06
Return on Assets (ROA)-0.06
Return on Invested Capital (ROIC)-7.47%
Return on Capital Employed (ROCE)-0.12
Revenue Per Employee0.00
Profits Per Employee-1.17M
Employee Count37
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of PYC Therapeutics Limited is ―. PYC Therapeutics Limited’s PEG ratio is 0.70.
PE Ratio―
PS Ratio0.00
PB Ratio1.79
Price to FCF-27.48
Price to Operating Cash Flow-39.32
PEG Ratio0.70
Income Statement
In the last 12 months, PYC Therapeutics Limited had revenue of 0.00 and earned -43.34M in profits. Earnings per share was -0.06.
Revenue0.00
Gross Profit-1.20M
Operating Income-82.67M
Pretax Income-69.76M
Net Income-43.34M
EBITDA-81.47M
Earnings Per Share (EPS)-0.06
Cash Flow
In the last 12 months, operating cash flow was -44.52M and capital expenditures -531.40K, giving a free cash flow of -45.05M billion.
Operating Cash Flow-44.52M
Free Cash Flow-45.05M
Free Cash Flow per Share-0.05
Dividends & Yields
PYC Therapeutics Limited pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.55
52-Week Price Change49.45%
50-Day Moving Average2.34
200-Day Moving Average1.68
Relative Strength Index (RSI)30.68
Average Volume (3m)4.85M
Important Dates
PYC Therapeutics Limited upcoming earnings date is Mar 1, 2027, TBA (Confirmed).
Last Earnings DateAug 28, 2026
Next Earnings DateMar 1, 2027
Ex-Dividend Date―
Financial Position
PYC Therapeutics Limited as a current ratio of 33.48, with Debt / Equity ratio of 0.09%
Current Ratio33.48
Quick Ratio33.48
Debt to Market Cap<0.01
Net Debt to EBITDA0.65
Interest Coverage Ratio-2.04K
Taxes
In the past 12 months, PYC Therapeutics Limited has paid -25.99M in taxes.
Income Tax-25.99M
Effective Tax Rate0.37
Enterprise Valuation
PYC Therapeutics Limited EV to EBITDA ratio is -14.55, with an EV/FCF ratio of -26.31.
EV to Sales0.00
EV to EBITDA-14.55
EV to Free Cash Flow-26.31
EV to Operating Cash Flow-26.62
Balance Sheet
PYC Therapeutics Limited has AU$447.56M in cash and marketable securities with AU$624.99K in debt, giving a net cash position of AU$446.94M billion.
Cash & Marketable SecuritiesAU$447.56M
Total DebtAU$624.99K
Net CashAU$446.94M
Net Cash Per ShareAU$0.45
Tangible Book Value Per ShareAU$0.94
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for PYC Therapeutics Limited is AU$4.13, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetAU$4.13
Price Target Upside98.72% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast39.63%